Needham & Company LLC Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued on Friday,Benzinga reports. They presently have a $6.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective points to a potential upside of 166.67% from the company’s current price.

A number of other equities analysts also recently issued reports on ESPR. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock opened at $2.25 on Friday. The stock has a market cap of $443.34 million, a price-to-earnings ratio of -3.52 and a beta of 1.01. The firm’s 50-day moving average is $2.39 and its two-hundred day moving average is $2.22. Esperion Therapeutics has a 1 year low of $1.58 and a 1 year high of $3.94.

Institutional Trading of Esperion Therapeutics

A number of institutional investors have recently modified their holdings of the company. Wasatch Advisors LP raised its stake in shares of Esperion Therapeutics by 38.4% during the 3rd quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after acquiring an additional 6,483,070 shares in the last quarter. Geode Capital Management LLC grew its holdings in Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after purchasing an additional 171,609 shares during the last quarter. Marshall Wace LLP increased its position in shares of Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. State Street Corp lifted its holdings in shares of Esperion Therapeutics by 2.7% during the 3rd quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Esperion Therapeutics by 71.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock worth $1,174,000 after purchasing an additional 295,378 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.